^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BMS-986288

i
Other names: BMS-986288, Anti-CTLA-4 NF Probody Therapeutic
Associations
Trials
Company:
BMS, CytomX
Drug class:
CTLA4 inhibitor
Associations
Trials
2ms
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (clinicaltrials.gov)
P1/2, N=219, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=494 --> 219 | Trial completion date: May 2025 --> Aug 2024
Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • Stivarga (regorafenib) • BMS-986288
4ms
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (clinicaltrials.gov)
P1/2, N=494, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Jun 2024 --> Oct 2024
Trial primary completion date • Combination therapy • Metastases
|
Opdivo (nivolumab) • Stivarga (regorafenib) • BMS-986288
7ms
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (clinicaltrials.gov)
P1/2, N=494, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Opdivo (nivolumab) • Stivarga (regorafenib) • BMS-986288
over4years
[VIRTUAL] Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index (AACR-II 2020)
Background: Blockade of the CTLA-4 pathway with ipilimumab (IPI) as monotherapy or in combination with nivolumab (anti–PD-1) is an effective treatment for a variety of cancers...Here, we describe the preclinical characterization of 2 novel anti–CTLA-4 PB mAbs: anti–CTLA-4 PB (BMS-986249) is a peptide-masked version of IPI, and anti‒CTLA-4 nonfucosylated (NF) PB (BMS-986288) is a peptide-masked version of anti–CTLA-4 NF, which has enhanced antibody-dependent cellular cytotoxicity (ADCC) and regulatory T-cell (Treg) depletion compared with IPI. Antibody binding to CD16 was studied by surface plasmon resonance... These data demonstrate the potential of the PB-Tx technology platform to improve the therapeutic indices of anti–CTLA-4 PB and anti–CTLA-4 NF PB relative to their parental mAbs. The safety and antitumor activity of anti–CTLA-4 PB (NCT03369223) and anti–CTLA-4 NF PB (NCT03994601) are being investigated in patients with advanced solid cancers in ongoing phase 1 studies.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986249 • BMS-986288